Puma Biotechnology Inc — Liquidità (NASDAQ:PBYI) | MetaTrader

Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche

Trimestrale Annuale

Flusso di cassa derivante dalle attività operative 773 K20.65 M-15.83 M27.01 M38.92 M41.8 M 41.8 M Flussi di cassa derivanti dalle attività di investimento 23.4 M-10.88 M7.1 M-19.13 M-20.44 M-36.19 M -36.19 M Liquidità derivante dalle attività di finanziamento 68 K-31.93 M12.22 M0-33.85 M-45.2 M -45.2 M Liquidità libera -19.23 M20.65 M-15.83 M14.37 M38.86 M41.73 M 41.73 M

Puma Biotechnology Inc

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Notizie

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last?

Puma Biotechnology Q4 2025: fatturato NERLYNX +15% sequenziale

Puma Biotechnology riporta solidi risultati per il Q4 2025

Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?

Puma Biotech alla Conferenza TD Cowen: Crescita Strategica e Disciplina Finanziaria

PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View

Puma Biotechnology, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:PBYI) 2026-02-27

Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates

Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates

Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates